White House Announces TrialReach to Support Cancer Moonshot Initiative
New York, NY and London UK (PRWEB) June 29, 2016 -- In conjunction with today’s Cancer Moonshot (#CancerMoonshot) Summit in Washington, DC, the White House announced that health tech startup TrialReach will be supporting a new plan for re-designing how patients and oncologists find and learn about cancer clinical trials through its new trial matching platform.
The mission of the Cancer Moonshot is to double the rate of progress towards a cure for cancer. Critical to this effort is addressing the problem that less than 4% of cancer patients take part in clinical trials and more than 80% of trials are closed or delayed due to difficulty finding patients to take part.
TrialReach is working closely with the White House to leverage newly public NCI data that features the most up-to-date and easy-to-understand descriptions of trials, in combination with the TrialReach’s database of structured clinical trial eligibility criteria. The result will be an online platform through which patients can be precisely matched to trials by answering questions about their cancer.
As TrialReach develops this new tool, they’re looking for people living with lung cancer to provide valuable input. Patients who are interested in getting a first look at the product and helping TrialReach ensure it meets patient needs in the most effective way possible can feel free to email patients(at)trialreach(dot)com.
In the fall of 2016, this state-of-the-art cancer trial matching tool will be available to lung cancer patients through an extensive network of online partners. Additional therapeutic areas – including all cancers – will follow.
“When I was diagnosed with stage IV kidney cancer, a clinical trial helped save my life,” said Dave deBronkart, Patient Perspectives Advisor for TrialReach. “But most cancer patients are not aware that a trial may even be an option for them, much less how to find one quickly when everything is on the line. TrialReach’s work with the Cancer Moonshot team aims to fix this, so researchers and the ultimate stakeholders, patients, can connect. To me, it’s an essential step in helping this vital project achieve its potential.”
“This is a watershed moment in cancer research, and we are honored to be part of it,” said TrialReach CEO Pablo Graiver. “We envision a day when medical research is mainstream, research is faster and more efficient, and cures seem within reach.”
###
About TrialReach
TrialReach is helping advance medical science by transforming the way patients connect with it, so that new drugs and life-saving treatments can reach the people who need them, faster.
TrialReach’s smart match technology is making all clinical trials machine-readable and searchable. What this means is that for the first time, patients can search thousands of trials in seconds to find a trial for them, just by answering a few simple, health-related questions. By democratizing the clinical trial matching process in this way, TrialReach is empowering patients and helping to drive medical science forward.
TrialReach was launched in 2009 and is based in the U.S. and the U.K. For more information, visit http://www.trialreach.com.
TrialReach Media Contacts
Sarah Kerruish
Chief Strategy and Growth Officer
+44 7546364484
sarah(at)trialreach(dot)com
Lisa Brockway
Director of Communications
(215) 872-2917
lisa(at)trialreach(dot)com
Lisa Brockway, TrialReach, http://www.trialreach.com, +1 (215) 872-2917, [email protected]
Share this article